Patents by Inventor Anne B. Jefferson

Anne B. Jefferson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8772255
    Abstract: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: July 8, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Timothy S. Burkoth, Anne B. Jefferson, Christoph Reinhard, Ronald N. Zuckermann
  • Publication number: 20090143322
    Abstract: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.
    Type: Application
    Filed: March 21, 2008
    Publication date: June 4, 2009
    Applicant: CHIRON CORPORATION
    Inventors: Timothy S. Burkoth, Anne B. Jefferson, Christoph Reinhard, Ronald N. Zuckermann
  • Patent number: 7501244
    Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: March 10, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Christoph Reinhard, Anne B. Jefferson, Vivien W. Chan
  • Patent number: 7501242
    Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: March 10, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Christoph Reinhard, Anne B. Jefferson, Vivien W. Chan
  • Patent number: 7501243
    Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: March 10, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Christoph Reinhard, Anne B. Jefferson, Vivien W. Chan
  • Patent number: 7476506
    Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: January 13, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Siew C. Schleyer, Anne B. Jefferson, Judith A. Abraham, W. Michael Kavanaugh
  • Patent number: 7422861
    Abstract: Different-sequence peptoids, including lipid- and sterol-conjugated peptoids, are found to be effective in transfection of cells with oligonucleotides. Combinatorial libraries of such peptoids can be screened efficiently in a high-throughput format, and selected peptoids are identified post-screening.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: September 9, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Ronald N. Zuckermann, Christoph J. Reinhard, Anne B Jefferson, Eric Beausoleil
  • Patent number: 7198899
    Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: April 3, 2007
    Assignee: Chiron Corporation
    Inventors: Siew C. Schleyer, Anne B. Jefferson, Judith A. Abraham, W. Michael Kavanaugh
  • Patent number: 6809194
    Abstract: Inhibitors of human Akt3, including antisense oligonucleotides, methods, and compositions specific for human Akt3, are provided. Methods of using the compositions for modulating Akt3 expression and for regulating cell growth, particularly tumor cell growth, are also provided.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: October 26, 2004
    Assignee: Chiron Corporation
    Inventors: Christoph Reinhard, Anne B. Jefferson
  • Publication number: 20040019004
    Abstract: Inhibitors of laminin5beta3 are provided that reduce the expression or biological activities of laminin5beta3 or the expression of laminin5beta3 mRNA in a mammalian cell. Laminin5beta3 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. Laminin5beta3 inhibitors find use in compositions and methods for decreasing laminin5beta3 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells of epithelial origin, and methods for treating neoplastic diseases.
    Type: Application
    Filed: March 14, 2003
    Publication date: January 29, 2004
    Applicant: Chiron Corporation
    Inventors: Christoph J. Reinhard, Anne B. Jefferson, Douglas R. Den-Otter, Jill A. Winter
  • Publication number: 20040005622
    Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
    Type: Application
    Filed: June 3, 2003
    Publication date: January 8, 2004
    Applicant: Chiron Corporation
    Inventors: Siew C. Schleyer, Anne B. Jefferson, Judith A. Abraham, W. Michael Kavanaugh
  • Patent number: 6586244
    Abstract: Inhibitors of laminin5beta3 are provided that reduce the expression or biological activities of laminin5beta3 or the expression of laminin5beta3 mRNA in a mammalian cell. Laminin5beta3 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. Laminin5beta3 inhibitors find use in compositions and methods for decreasing laminin5beta3 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells of epithelial origin, and methods for treating neoplastic diseases.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: July 1, 2003
    Assignee: Chiron Corporation
    Inventors: Christoph J. Reinhard, Anne B. Jefferson, Douglas R. Den-Otter, Jill A. Winter
  • Publication number: 20030045491
    Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.
    Type: Application
    Filed: February 21, 2002
    Publication date: March 6, 2003
    Inventors: Christoph Reinhard, Anne B. Jefferson, Vivien W. Chan
  • Publication number: 20020156035
    Abstract: Modulators of NET-4 are provided that reduce the expression or biological activities of NET-4 or the expression of NET-4 mRNA in a mammalian cell. NET-4 modulators include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. NET-4 modulators find use in compositions and methods for decreasing NET-4 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells, and methods for treating neoplastic diseases.
    Type: Application
    Filed: June 5, 2001
    Publication date: October 24, 2002
    Inventors: Christoph Reinhard, Anne B. Jefferson, Jill A. Winter, Filippo Randazzo
  • Publication number: 20020151062
    Abstract: Different-sequence peptoids, including lipid- and sterol-conjugated peptoids, are found to be effective in transfection of cells with oligonucleotides. Combinatorial libraries of such peptoids can be screened efficiently in a high-throughput format, and selected peptoids are identified post-screening.
    Type: Application
    Filed: December 18, 2001
    Publication date: October 17, 2002
    Inventors: Ronald N. Zuckermann, Christoph J. Reinhard, Anne B. Jefferson, Eric Beausoleil
  • Publication number: 20020052334
    Abstract: Inhibitors of laminin5beta3 are provided that reduce the expression or biological activities of laminin5beta3 or the expression of laminin5beta3 mRNA in a mammalian cell. Laminin5beta3 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. Laminin5beta3 inhibitors find use in compositions and methods for decreasing laminin5beta3 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells of epithelial origin, and methods for treating neoplastic diseases.
    Type: Application
    Filed: June 6, 2001
    Publication date: May 2, 2002
    Inventors: Christoph J. Reinhard, Anne B. Jefferson, Douglas R. Den-Otter, Jill A. Winter